CR10357A - Proceso para la preparacion de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1) - Google Patents

Proceso para la preparacion de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)

Info

Publication number
CR10357A
CR10357A CR10357A CR10357A CR10357A CR 10357 A CR10357 A CR 10357A CR 10357 A CR10357 A CR 10357A CR 10357 A CR10357 A CR 10357A CR 10357 A CR10357 A CR 10357A
Authority
CR
Costa Rica
Prior art keywords
subtipo
indazolil
ureas
preparation
vanilloid receptors
Prior art date
Application number
CR10357A
Other languages
English (en)
Inventor
Kirill A Lukin
Hsu Margaret Chi-Ping
Brian J Kotecki
Marvin R Leanna
Dilinie P Fernando
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CR10357A publication Critical patent/CR10357A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un proceso de preparar indazolilureas que son utiles como antagonistas del receptor de vainilloides de subtipo 1 (VR1).
CR10357A 2006-04-14 2008-10-08 Proceso para la preparacion de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1) CR10357A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79209906P 2006-04-14 2006-04-14

Publications (1)

Publication Number Publication Date
CR10357A true CR10357A (es) 2008-12-11

Family

ID=38610399

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10357A CR10357A (es) 2006-04-14 2008-10-08 Proceso para la preparacion de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)

Country Status (21)

Country Link
US (2) US7847104B2 (es)
EP (1) EP2012779B1 (es)
JP (1) JP2009533474A (es)
KR (2) KR101118932B1 (es)
CN (4) CN102321025A (es)
AU (1) AU2007238019B2 (es)
BR (1) BRPI0709963A2 (es)
CA (1) CA2647261A1 (es)
CR (1) CR10357A (es)
EC (1) ECSP088878A (es)
ES (1) ES2385404T3 (es)
HK (1) HK1123725A1 (es)
MX (1) MX2008013205A (es)
MY (1) MY145334A (es)
NO (1) NO20084698L (es)
NZ (1) NZ571705A (es)
RU (1) RU2446161C2 (es)
TW (1) TW200815362A (es)
UA (1) UA94100C2 (es)
WO (1) WO2007121339A2 (es)
ZA (1) ZA200808596B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2214675B1 (en) * 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
JP2011515414A (ja) * 2008-03-20 2011-05-19 アボット・ラボラトリーズ Ｔｒｐｖ１アンタゴニストである中枢神経系薬剤を作製する方法
CN102070420B (zh) * 2011-01-04 2013-12-18 常州大学 一种2-溴-6-氟苯甲醛的制备方法
WO2014158640A1 (en) * 2013-03-13 2014-10-02 Dow Agrosciences Llc Improved process for the preparation of certain triaryl rhamnose carbamates
CN109476646A (zh) 2016-07-12 2019-03-15 拜耳作物科学股份公司 作为害虫防治剂的双环化合物
CN106977535A (zh) * 2017-04-28 2017-07-25 大连联化化学有限公司 一种合成2‑氰基3‑氟苯硼酸工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (es) * 1963-08-09
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
EP0714389B1 (en) * 1993-08-20 1998-06-17 Smithkline Beecham Plc Amide and urea derivatives as 5ht1d receptor antagonists
WO2003035065A1 (en) * 2001-10-26 2003-05-01 Aventis Pharmaceuticals Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
EP1499599A1 (en) 2002-04-26 2005-01-26 Pharmacia & Upjohn Company LLC Substituted pyrazine derivatives
PT1638941E (pt) * 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7226941B2 (en) * 2003-06-30 2007-06-05 Hif Bio, Inc. Compound for treating angiogenesis
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
WO2006020070A2 (en) * 2004-07-16 2006-02-23 Teva Pharmaceutical Industries, Ltd. Indanylamino uracils and their use as antioxidants and neuroprotectants
US20070021450A1 (en) * 2004-07-16 2007-01-25 Benjamin Sklarz Indanylamino uracils and their use as antioxidants and neuroprotectants
CA2618513A1 (en) * 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
CN101316818B (zh) * 2005-11-30 2011-08-31 弗·哈夫曼-拉罗切有限公司 3-氨基-1-芳基丙基吲哚类和氮杂取代的吲哚类

Also Published As

Publication number Publication date
EP2012779A4 (en) 2010-11-24
CN102775350A (zh) 2012-11-14
AU2007238019A1 (en) 2007-10-25
KR20110017464A (ko) 2011-02-21
AU2007238019B2 (en) 2013-03-14
NZ571705A (en) 2012-03-30
CN102140081A (zh) 2011-08-03
CN101466374B (zh) 2012-03-21
US8519186B2 (en) 2013-08-27
CN101466374A (zh) 2009-06-24
BRPI0709963A2 (pt) 2011-08-02
UA94100C2 (ru) 2011-04-11
HK1123725A1 (en) 2009-06-26
US20110040102A1 (en) 2011-02-17
ECSP088878A (es) 2008-12-30
EP2012779B1 (en) 2012-05-16
KR101118932B1 (ko) 2012-02-27
MY145334A (en) 2012-01-31
ZA200808596B (en) 2010-03-31
KR20090003335A (ko) 2009-01-09
EP2012779A2 (en) 2009-01-14
ES2385404T3 (es) 2012-07-24
US20070244178A1 (en) 2007-10-18
CN102321025A (zh) 2012-01-18
RU2446161C2 (ru) 2012-03-27
WO2007121339A2 (en) 2007-10-25
CA2647261A1 (en) 2007-10-25
RU2008144961A (ru) 2010-05-20
WO2007121339A3 (en) 2008-10-02
MX2008013205A (es) 2008-10-22
NO20084698L (no) 2008-11-07
JP2009533474A (ja) 2009-09-17
TW200815362A (en) 2008-04-01
US7847104B2 (en) 2010-12-07

Similar Documents

Publication Publication Date Title
ECSP088989A (es) (aza)ciclohexanos carboxilados nuevos como ligandos de receptores de dopamina d3
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
UY32996A (es) Antagonistas del receptor crth2 basados en indol
ECSP088878A (es) Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
DOP2009000149A (es) Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
UY34530A (es) Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1)
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
ECSP11011433A (es) Fenilureas y fenilamidas sustituidas como ligandos del receptor de vanilloides
UA107360C2 (en) Bicyclic aryl sphingosine 1-phosphate analogs
EA201501122A1 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
HN2008000646A (es) Antagonistas de los receptores 2 de dopamina de rapida disociacion
AR061727A1 (es) Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
CO6470826A2 (es) Moduladores de lxr
ECSP099692A (es) Ligandos de receptor de vainilloide novedosos y su uso de los mismos para la produccion de sustancias farmaceuticas
CL2009000532A1 (es) Compuestos derivados de piridin-2-ilo; agonista del receptor s1p1/edg1; composición farmacéutica que los comprende; uso en trastornos asociados con el sitema inmunitario.
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
CR10540A (es) Derivados ciclopropil amina
ECSP13012495A (es) Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina
CR9923A (es) Compuestos triciclicos utiles como agonistas de receptores de oxitocina
CR11828A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)